SAN FRANCISCO, June 10, 2026
Matter Bio has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for LM-LLO-TT, an innovative attenuated Listeria monocytogenes-based immunotherapy being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). The regulatory clearance enables the biotechnology company to initiate its first-in-human Phase 1/2a clinical trial, marking a significant milestone in the advancement of a novel immunotherapy approach for one of the most aggressive and difficult-to-treat forms of cancer. The achievement also officially transitions Matter Bio into a clinical-stage biotechnology company, positioning it to generate the first clinical evidence supporting the potential of its proprietary immunotherapy platform in pancreatic cancer.
FDA Clearance Opens First-in-Human Clinical Development Program
The FDA’s clearance of the IND application allows Matter Bio to begin a Phase 1/2a clinical study designed to evaluate the safety, tolerability, dose optimization, and preliminary anti-tumor activity of LM-LLO-TT in patients diagnosed with pancreatic ductal adenocarcinoma. The study represents the first time the investigational therapy will be tested in humans and is expected to provide critical insights into its clinical profile and therapeutic potential. Pancreatic ductal adenocarcinoma remains one of the deadliest cancers globally, characterized by late diagnosis, limited treatment options, poor survival outcomes, and high resistance to conventional therapies.
As a result, the development of innovative immunotherapeutic approaches capable of stimulating effective anti-tumor immune responses has become a major focus across the oncology industry. By advancing LM-LLO-TT into clinical evaluation, Matter Bio aims to address a significant unmet medical need and contribute to the growing field of next-generation cancer immunotherapies.
Novel Listeria-Based Immunotherapy Targets Tumor Immune Responses
Advertisement
LM-LLO-TT is built on an attenuated Listeria monocytogenes platform, a technology engineered to activate and direct the immune system against tumor-associated antigens. The investigational therapy is designed to stimulate robust tumor-directed immune responses, potentially enabling the immune system to recognize and attack cancer cells more effectively. Unlike traditional treatment approaches that directly target tumor growth, immunotherapies seek to harness the body’s natural defense mechanisms to achieve durable anti-cancer activity. Matter Bio believes its platform may offer a differentiated strategy for treating cancers that have historically shown limited responsiveness to existing immunotherapy options.
The upcoming clinical trial will focus on establishing an optimal dose while generating early signals of biological activity and clinical benefit. Successful outcomes could support broader development efforts and potentially position LM-LLO-TT as a promising therapeutic candidate within the rapidly expanding oncology immunotherapy landscape.
Advancing Innovation in One of Oncology’s Greatest Challenges
The IND clearance follows Matter Bio’s previously announced regulatory submission and reflects the company’s continued execution of its clinical development strategy. Company leadership highlighted the achievement as the culmination of extensive efforts across scientific, regulatory, manufacturing, and clinical development teams. The milestone comes at a time when pharmaceutical and biotechnology companies are increasingly investing in novel immune-based approaches to address hard-to-treat solid tumors. Pancreatic ductal adenocarcinoma remains a particularly challenging target due to its immunosuppressive tumor microenvironment and historically poor response to many therapies. By leveraging a unique microbial immunotherapy platform, Matter Bio seeks to overcome these barriers and expand treatment possibilities for patients with limited therapeutic options.
The initiation of clinical testing represents a critical next step in determining whether LM-LLO-TT can deliver meaningful clinical benefit and establish a foundation for future development programs. As the biotechnology sector continues to pursue innovative cancer treatment strategies, Matter Bio’s advancement into human trials highlights growing momentum in the development of next-generation immunotherapies designed to improve outcomes for patients facing some of the most difficult cancers.
Source: Matter Bio press release
